Definition
The B-cell receptor (BCR) is a membrane-bound immunoglobulin molecule expressed on the surface of B lymphocytes that serves to recognize specific antigens and initiate B-cell activation, proliferation, and differentiation.
Overview
BCRs are central to the adaptive immune response. Each naïve B cell displays a unique BCR generated through somatic recombination of immunoglobulin gene segments, enabling the immune system to recognize an immense diversity of antigens. Upon binding its cognate antigen, the BCR transduces intracellular signals that promote clonal expansion, antibody production, class-switch recombination, and affinity maturation. BCR signaling is modulated by co-receptors (e.g., CD19, CD21, CD81) and by downstream kinases such as Lyn, Syk, and Bruton’s tyrosine kinase (BTK). Dysregulation of BCR signaling can contribute to immunodeficiency, autoimmunity, and B‑cell malignancies.
Etymology/Origin
The term combines “B‑cell,” referring to the lymphocyte lineage that matures in the bone marrow and produces antibodies, with “receptor,” a protein structure that binds a specific ligand. The abbreviation “BCR” has been in common usage in immunology literature since the late 20th century, following the parallel naming of the T‑cell receptor (TCR).
Characteristics
| Feature | Description |
|---|---|
| Molecular composition | Membrane‑bound immunoglobulin (IgM or IgD on naïve B cells) non‑covalently associated with the heterodimeric signaling subunits CD79a (Igα) and CD79b (Igβ). |
| Structure | Composed of two identical heavy chains and two identical light chains forming antigen‑binding Fab regions, plus a transmembrane domain linked to CD79 heterodimers containing immunoreceptor tyrosine‑based activation motifs (ITAMs). |
| Antigen specificity | Determined by the variable (V) regions generated through V(D)J recombination, junctional diversity, and somatic hypermutation. |
| Signaling cascade | Antigen binding induces conformational changes → Src‑family kinase Lyn phosphorylates ITAMs → recruitment of Syk → activation of PLCγ2, NF‑κB, MAPK, and PI3K pathways. |
| Expression pattern | Naïve B cells co‑express IgM and IgD BCRs; activated or class‑switched B cells display IgG, IgA, or IgE BCRs. |
| Regulation | Negative regulators include phosphatases (SHP‑1), inhibitory co‑receptors (FcγRIIB), and feedback from cytokines. |
| Clinical relevance | Targeted by therapeutics such as BTK inhibitors (ibrutinib) and anti‑CD20 antibodies (rituximab) in treating B‑cell lymphomas and autoimmune diseases. |
Related Topics
- Immunoglobulin (antibody) – soluble form of the BCR that mediates extracellular antigen neutralization.
- T‑cell receptor (TCR) – analogous membrane receptor on T lymphocytes recognizing peptide‑MHC complexes.
- V(D)J recombination – genetic mechanism generating BCR diversity.
- Somatic hypermutation and affinity maturation – processes that refine BCR specificity after antigen exposure.
- B‑cell development – stages from progenitor to mature naïve B cell, during which BCR expression is a key checkpoint.
- B‑cell malignancies – diseases such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma in which BCR signaling is often constitutively active.
- Autoimmune disorders – conditions like systemic lupus erythematosus where aberrant BCR signaling contributes to autoantibody production.